Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Mark Lackner Sells 4,411 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Mark Lackner sold 4,411 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.12, for a total transaction of $13,762.32. Following the transaction, the insider now owns 191,317 shares in the company, valued at $596,909.04. This trade represents a 2.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zentalis Pharmaceuticals Stock Up 8.0 %

Shares of ZNTL stock opened at $3.24 on Friday. The firm has a market cap of $230.90 million, a price-to-earnings ratio of -1.30 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 52-week low of $2.66 and a 52-week high of $18.07. The company’s 50 day moving average is $3.33 and its 200 day moving average is $3.51.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. Analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Bank of New York Mellon Corp boosted its holdings in Zentalis Pharmaceuticals by 15.1% during the second quarter. Bank of New York Mellon Corp now owns 333,719 shares of the company’s stock worth $1,365,000 after buying an additional 43,839 shares in the last quarter. Rhumbline Advisers lifted its holdings in Zentalis Pharmaceuticals by 13.8% in the 2nd quarter. Rhumbline Advisers now owns 94,213 shares of the company’s stock valued at $385,000 after purchasing an additional 11,451 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 117.6% in the second quarter. Los Angeles Capital Management LLC now owns 83,717 shares of the company’s stock worth $342,000 after buying an additional 45,249 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $95,000. Finally, Renaissance Technologies LLC grew its holdings in Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after buying an additional 399,745 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently commented on ZNTL. Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.